Mylotarg, fludarabine, cytarabine (Ara-C) and cyclosporine (MFAC) combination regimen in patients with CD33-positive primary resistant or relapsed acute myeloid leukemia (AML).

被引：0
|
作者：
Tsimberidou, AM [1 ]
Estey, E [1 ]
Cortes, J [1 ]
Thomas, D [1 ]
Garcia-Manero, G [1 ]
Faderl, S [1 ]
Verstovesk, S [1 ]
O'Brien, S [1 ]
Kantarjian, H [1 ]
Giles, F [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1317
引用
收藏
页码：339A / 340A
页数：2
相关论文
共 50 条
  • [1] Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia
    Apostolia M. Tsimberidou
    Elihu Estey
    Jorge E. Cortes
    Guillermo Garcia-Manero
    Stefan Faderl
    Srdan Verstovsek
    Deborah A. Thomas
    Alessandra Ferrajoli
    Michael J. Keating
    Susan O'Brien
    Hagop M. Kantarjian
    Francis J. Giles
    Cancer Chemotherapy and Pharmacology, 2003, 52 : 449 - 452
  • [2] Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia
    Tsimberidou, AM
    Estey, E
    Cortes, JE
    Garcia-Manero, G
    Faderl, S
    Verstovsek, S
    Thomas, DA
    Ferrajoli, A
    Keating, MJ
    O'Brien, S
    Kantarjian, HM
    Giles, FJ
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 52 (06) : 449 - 452
  • [3] Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+primary resistant or relapsed acute myeloid leukemia
    Tsimberidou, A
    Cortes, J
    Thomas, D
    Garcia-Manero, G
    Verstovsek, S
    Faderl, S
    Albitar, M
    Kantarjian, H
    Estey, E
    Giles, FJ
    LEUKEMIA RESEARCH, 2003, 27 (10) : 893 - 897
  • [4] Feasibility of mylotarg, fludarabine, ara-C and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia (AML).
    Tsimberidou, AM
    Estey, E
    Cortes, J
    Thomas, D
    Garcia-Manero, G
    Faderl, S
    Verstovsek, S
    O'Brien, S
    Kantarjian, H
    Giles, F
    BLOOD, 2002, 100 (11) : 339A - 339A
  • [5] Mylotarg, liposomal daunorubicin, Ara-C and cyclosporine (MDAC) regimen in patients with relapsed/refractory acute myelogenous leukemia (AML)
    Apostolidou, E
    Cortes, J
    Tsimberidou, AM
    Estey, E
    Kantarjian, H
    Giles, F
    BLOOD, 2002, 100 (11) : 268B - 268B
  • [6] Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia
    Alvarado, Y
    Tsimberidou, A
    Kantarjian, H
    Cortes, J
    Garcia-Manero, G
    Faderl, S
    Thomas, D
    Estey, E
    Giles, FJ
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 51 (01) : 87 - 90
  • [7] Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia
    Yesid Alvarado
    Apostolia Tsimberidou
    Hagop Kantarjian
    Jorge Cortes
    Guillermo Garcia-Manero
    Stefan Faderl
    Deborah Thomas
    Elihu Estey
    Francis J. Giles
    Cancer Chemotherapy and Pharmacology, 2003, 51 : 87 - 90
  • [8] Mylotarg, fludarabine, ara-C and cyclosporine (MFAC) in patients with newly diagnosed acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (MDS).
    Tsimberidou, AM
    Estey, E
    Cortes, J
    Thomas, D
    Garcia-Manero, G
    Faderl, S
    Verstovsek, S
    O'Brien, S
    Kantarjian, H
    Giles, F
    BLOOD, 2002, 100 (11) : 339A - 339A
  • [9] FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
    Norsworthy, Kelly J.
    Ko, Chia-Wen
    Lee, Jee Eun
    Liu, Jiang
    John, Christy S.
    Przepiorka, Donna
    Farrell, Ann T.
    Pazdur, Richard
    ONCOLOGIST, 2018, 23 (09): : 1103 - 1108
  • [10] CLOFARABINE IN COMBINATION WITH CYTARABINE (ARA-C) FOR TREATMENT OF RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA IN ADULT PATIENTS
    Malato, A.
    Santoro, A.
    Magrin, S.
    Felice, R.
    Turri, D.
    Di Bella, R.
    Salemi, D.
    Acquaviva, F.
    Scime, R.
    Fabbiano, F.
    HAEMATOLOGICA, 2012, 97 : 502 - 503
12345